Management
BIOCRATES is lead by a highly experienced and dedicated team of experts, ready to lead Biocrates into the next growth phase.
Elgar Schnegg, MBA
Chief Executive Officer
Elgar Schnegg joined BIOCRATES in 2008 as chief executive officer. Mr Schnegg has an outstanding track record in the pharmaceutical and FMCG (fast moving consumer goods) industries. Before 2008, Mr Schnegg was managing director of Sandoz Austria (Novartis), leading a three-brand organization (Sandoz, Hexal, 1A) into the top 10 of national pharmaceutical companies. Before, Elgar Schnegg had spent several years in the FMCG industry as general manager of international business for Head AG. He started his career with Eli Lilly Inc., a leading research-based pharmaceutical company, moving through the sales and marketing ranks to eventually lead a foreign subsidiary business as managing director . Mr Schnegg, who graduated from Innsbruck University with a degree in economics and completed an MBA at the University of Dallas, Texas, also teaches MBA courses as part of the biotech program at the University of Krems, Austria.
Klaus Weinberger, PhD
Chief Scientific Officer
Klaus Weinberger is a biomedical scientist with particular expertise in metabolomics, infectious diseases, public health, and immunology. Dr Weinberger joined Biocrates as chief scientific officer in 2003. Before that, he led a research group specializing in clinical virology, infection immunology, and molecular epidemiology at the Institute for Medical Microbiology and Hygiene at the University of Regensburg, Germany. His personal focus was on implementing innovative technologies and bioinformatics tools in biomedical research. Dr Weinberger holds a PhD in medical microbiology from the University of Regensburg. He serves as a referee for scientific journals and European public science funding organizations. He has been awarded the triennial Saul-Krugman-Award for substantial contributions to molecular and clinical hepatitis virology (Atlanta, 2000), memberships of the WHO reference center for viral hepatitis (Regensburg, 1996) and the WHO collaborating center for virus-associated cancer (Regensburg, 1994), and a 5-year-scholarship by the Bavarian Ministry of Education (Munich, 1989–1994).
